Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Oxford Immunotec Announces appointment of President – North America
and filing for FDA approval for T-SPOT.TB


Oxford, UK; 19th March 2007 – Oxford Immunotec Ltd, the T cell measurement company, today announces that:

  • it has appointed Jeff Schroeder as President of its North American operations
  • it has completed its PMA filings with the FDA for approval of T-SPOT.TB for the US market

    Oxford Immunotec develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells. T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection.

    Jeff Schroeder has been appointed in order to build the sales & marketing infrastructure for the launch of T-SPOT.TB in the US market later this year. Before joining the Company he was Vice President Sales and Marketing for Cytyc Corporation, where he led the product marketing team to develop and implement the strategic plan for the ThinPrep Pap Test and the ThinPrep Imaging System. Prior to joining Cytyc, he spent two years as VP Sales and Marketing with Cytologix Corporation and six years in senior sales positions with Abbott Laboratories, culminating in his appointment as Director Worldwide Marketing Diagnostics Division.

    T-SPOT.TB will be launched following completion of the FDA’s review of the Company’s Pre Market Approval submission which was completed in January 2007. Approval will allow Oxford Immunotec to access the North American TB testing market currently estimated to be worth over $500 million.

    Commenting on the above, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “We are delighted that Jeff Schroeder has agreed to join the Company as we gear up to launch T-SPOT.TB in North America later this year.. His wealth of experience in the North American diagnostics space will allow Oxford Immunotec to successfully exploit the opportunity to access the world’s largest market for TB testing following FDA approval for T-SPOT.TB. Jeff will provide the necessary leadership to successfully develop the Group’s North American operations and will play a crucial role in establishing T-SPOT.TB as the new benchmark for TB screening”.
    - ENDS -


    Notes to editors:
    About Oxford Immunotec
    www.oxfordimmunotec.com
    Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

    T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

    About T-SPOT®.TB
    T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding $1bn.

    Unlike the traditional Tuberculin Skin Test, the T-SPOT.TB test incorporates a positive control, allowing the user to distinguish between a genuine negative result and one which is indeterminate (i.e. an inconclusive result) as a result of a technical failure.
    T-SPOT is a trademark of Oxford Immunotec.
    xx


    Publisher Contact Information:

    Oxford Immunotec Ltd.
    +44 (0)1235 442780
    info@oxfordimmunotec.com

    Company profile of Oxford Immunotec Ltd.
    Past press releases of Oxford Immunotec Ltd..

  • Data


    27,242
    Tech investments
    From our Online Data Service
    17,580
    VC-backed companies
    From our Radar


    Recent Deals


    DATEAMOUNTSECTOR
    Nov 25€24.0MInternet commerce
    Jul 31€2.8MInternet services
    Jul 30€9.5MWireless applications
    Jul 30€4.5MSensors
    Jul 30€5.0ME-Commerce
    Jul 30N/ANetwork management
    Jul 30€72.0MInternet services

    For information on Europe's most extensive database on technology funding click here!

    Events



    Press Releases


    May 28
    Identiq
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    Nethone
    nethone raised over $1 million from innovation nest

    Mar 31
    CompPair
    the fit allocates chf 100'000 to comppair technologies

    Jan 29
    Yumpingo
    yumpingo raises $10m to transform guest experiences in restaurants

    Oct 1
    The Link App
    the link app launches version 2.0





    About usContact usLegal Information
    Copyright © 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.